



# AGO-OVAR 2.21 ENGOT ov18




---

A prospective randomized Phase III trial of Carboplatin / Gemcitabine / Bevacizumab vs. Carboplatin / Pegylated Liposomal Doxorubicin / Bevacizumab in patients with platinum-sensitive recurrent ovarian cancer.  
An ENGOT / GCIIG Trial.

International Chair: Prof. Dr. med. Jacobus Pfisterer

EudraCT-No. 2012-004125-24

# Trial Design



## Stratification Factors

- ❖ Platinum free interval (6-12 months vs. > 12 months)
- ❖ In case of debulking surgery for recurrence: residual tumour (yes vs. no)  
In case of no debulking surgery for recurrence: all pts. categorized to residual tumor = yes
- ❖ prior antiangiogenetic treatment (yes vs. no)
- ❖ study group



# Timelines



---

No. Pts planned:            n = 654  
First Patient In:            01-Aug-2013 (AGO Study Group)  
Enrollment Period:        24 months  
PFS:                            ~ 12.5 months  
OS:                              ~ 33.3 months

## Participating Groups:

- GINECO → Start Q4/2013
- AGO Austria → Start Q4/2013
- SGCTG → Start Q1/2014
- ANZGOG → Start Q1/2014




# AGO-OVAR 2.21 ENGOT-ov18



## Recruitment Status

27-Sep-2013

AGO	17
GINECO	0
AGO Austria	0
SGCTG	0
ANZGOG	0





# AGO-OVAR 2.21 ENGOT-ov18



---

## AGO Study Group

International Chair: Prof. Dr. med. Jacobus Pfisterer, Kiel, Germany

Overall Trial Management  
AGO Study Group

Kaiser-Friedrich-Ring 71  
65185 Wiesbaden  
Germany  
Phone: +49 611 8804 67-0  
Fax: +49 611 8804 67-66

Moltkeplatz 63  
45138 Essen  
Germany  
Phone: +49 201 959812-0  
Fax: +49 201 959812-21

office-essen@ago-ovar.de  
www.ago-ovar.de